SRPT
Sarepta Therapeutics, Inc.
Price Chart
Latest Quote
$17.53
+0.57 (+3.36%)
Current Price
| Previous Close | $16.96 |
| Open | $17.05 |
| Day High | $18.00 |
| Day Low | $17.05 |
| Volume | 4,704,609 |
Stock Information
| Shares Outstanding | 105.58M |
| Total Debt | $1.05B |
| Cash Equivalents | $653.19M |
| Revenue | $2.18B |
| Net Income | $65.06M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.85B |
| P/E Ratio | 50.09 |
| EPS (TTM) | $0.35 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.06B |
| Sales | $2.18B |
| Income | $65.06M |
| Book/sh | $14.26 |
| Cash/sh | $6.19 |
| Employees | 835 |
Financial Ratios
| Quick Ratio | 2.41 |
| Current Ratio | 4.63 |
| Debt/Eq | 69.57 |
Returns & Margins
| ROA | 0.02% |
| ROE | 4.91% |
| Gross Margin | 21.55% |
| Operating Margin | 49.05% |
| Profit Margin | 2.98% |
Ownership
| Insider Ownership | 4.22% |
| Institutional Ownership | 99.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.43 |
| PEG | -0.09 |
| P/S | 0.85 |
| P/B | 1.23 |
Analyst Data
| Recommendation | hold |
| Target Price | $22.00 |
Technical Indicators
| SMA20 | $16.38 |
| SMA50 | $18.80 |
| SMA200 | $19.72 |
| RSI | 47.54 |
| ATR | 0.9029 |
| Shares Float | 94.61M |
| Short Float | 28.53% |
| Short Ratio | 8.51 |
| Volatility | 0.20 |
| Rel Volume | 1.90 |
Performance History
| Week | +16.87% |
| Month | +5.35% |
| Quarter | +5.29% |
| 6 Months | -21.43% |
| YTD | -17.74% |
| Year | -18.69% |
| 3 Years | -86.50% |
| 5 Years | -79.62% |
| 10 Years | -1.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $17.53 | 5,608,800 |
| 2026-06-17 | $16.96 | 4,512,900 |
| 2026-06-16 | $15.78 | 2,195,700 |
| 2026-06-15 | $15.77 | 2,311,700 |
| 2026-06-12 | $15.31 | 2,270,400 |
| 2026-06-11 | $15.00 | 2,758,800 |
| 2026-06-10 | $15.11 | 2,332,200 |
| 2026-06-09 | $15.89 | 2,437,100 |
| 2026-06-08 | $15.55 | 2,426,400 |
| 2026-06-05 | $15.75 | 2,739,900 |
| 2026-06-04 | $16.66 | 2,338,900 |
| 2026-06-03 | $16.24 | 3,542,600 |
| 2026-06-02 | $16.25 | 4,610,000 |
| 2026-06-01 | $17.61 | 3,098,300 |
| 2026-05-29 | $17.87 | 3,653,300 |
| 2026-05-28 | $17.30 | 2,931,300 |
| 2026-05-27 | $16.68 | 2,189,500 |
| 2026-05-26 | $16.67 | 3,089,300 |
| 2026-05-22 | $16.80 | 1,956,500 |
| 2026-05-21 | $16.96 | 2,021,600 |
| 2026-05-20 | $17.12 | 2,296,600 |
| 2026-05-19 | $16.64 | 2,292,400 |
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
MT Newswires âĸ 2026-06-18T15:04:44ZIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its PostâProfitability Playbook?
Simply Wall St. âĸ 2026-06-08T21:19:54Z
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Zacks âĸ 2026-06-08T16:00:05Z
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Zacks âĸ 2026-06-08T15:40:02Z
Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy
Insider Monkey âĸ 2026-06-06T00:18:11Z
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:30Z
In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities
Insider Monkey âĸ 2026-05-27T21:19:22Z
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-05-26T04:30:01Z
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Zacks âĸ 2026-05-22T15:10:00Z
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Zacks âĸ 2026-05-22T15:06:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $797,706,000 | $283,780,000 | $107,505,000 | $98,839,000 |
| Cost Of Revenue | $839,605,000 | $319,099,000 | $150,343,000 | $139,989,000 |
| Total Revenue | $2,198,237,000 | $1,901,979,000 | $1,243,336,000 | $933,013,000 |
| Operating Revenue | $2,198,237,000 | $1,901,979,000 | $1,243,336,000 | $933,013,000 |
| Expenses | ||||
| Interest Expense | $38,140,000 | $18,391,000 | $22,010,000 | $53,248,000 |
| Total Expenses | $2,856,009,000 | $1,683,898,000 | $1,511,160,000 | $1,469,214,000 |
| Other Non Operating Income Expenses | $-1,942,000 | $-60,000 | $101,090,000 | $-6,921,000 |
| Net Non Operating Interest Income Expense | $-1,450,000 | $53,376,000 | $63,959,000 | $-25,525,000 |
| Interest Expense Non Operating | $38,140,000 | $18,391,000 | $22,010,000 | $53,248,000 |
| Operating Expense | $2,016,404,000 | $1,364,799,000 | $1,360,817,000 | $1,329,225,000 |
| General And Administrative Expense | $491,716,000 | $557,872,000 | $481,871,000 | $451,421,000 |
| Other Income Expense | - | - | - | $-128,237,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Net Interest Income | $-1,450,000 | $53,376,000 | $63,959,000 | $-25,525,000 |
| Interest Income | $36,690,000 | $71,767,000 | $85,969,000 | $27,723,000 |
| Normalized Income | $-680,971,810 | $244,821,795 | $-206,291,830 | $-607,648,360 |
| Net Income From Continuing And Discontinued Operation | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Total Operating Income As Reported | $-699,781,000 | $218,081,000 | $-267,824,000 | $-536,201,000 |
| Net Income Common Stockholders | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Net Income | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Net Income Including Noncontrolling Interests | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Net Income Continuous Operations | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Pretax Income | $-702,225,000 | $260,774,000 | $-520,098,000 | $-689,963,000 |
| Special Income Charges | $-25,147,000 | $-7,838,000 | $-418,850,000 | $-121,316,000 |
| Interest Income Non Operating | $36,690,000 | $71,767,000 | $85,969,000 | $27,723,000 |
| Operating Income | $-657,772,000 | $218,081,000 | $-267,824,000 | $-536,201,000 |
| Depreciation Amortization Depletion Income Statement | $2,622,000 | $2,405,000 | $1,559,000 | $714,000 |
| Depreciation And Amortization In Income Statement | $2,622,000 | $2,405,000 | $1,559,000 | $714,000 |
| Amortization Of Intangibles Income Statement | $2,622,000 | $2,405,000 | $1,559,000 | $714,000 |
| Gross Profit | $1,358,632,000 | $1,582,880,000 | $1,092,993,000 | $793,024,000 |
| Per Share | ||||
| Diluted EPS | $-7.13 | $2.34 | $-5.80 | $-8.03 |
| Basic EPS | $-7.13 | $2.47 | $-5.80 | $-8.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $-8,622,810 | $-1,040,205 | $-87,637,830 | $-25,476,360 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-578,503,000 | $327,512,000 | $-36,368,000 | $-473,535,000 |
| Total Unusual Items | $-41,061,000 | $-10,623,000 | $-417,323,000 | $-121,316,000 |
| Total Unusual Items Excluding Goodwill | $-41,061,000 | $-10,623,000 | $-417,323,000 | $-121,316,000 |
| Reconciled Depreciation | $44,521,000 | $37,724,000 | $44,397,000 | $41,864,000 |
| EBITDA (Bullshit earnings) | $-619,564,000 | $316,889,000 | $-453,691,000 | $-594,851,000 |
| EBIT | $-664,085,000 | $279,165,000 | $-498,088,000 | $-636,715,000 |
| Diluted Average Shares | $97,494,000 | $107,875,000 | $92,398,000 | $87,559,000 |
| Basic Average Shares | $93,617,000 | $95,075,000 | $92,398,000 | $87,559,000 |
| Diluted NI Availto Com Stockholders | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Tax Provision | $11,185,000 | $25,535,000 | $15,879,000 | $13,525,000 |
| Other Special Charges | $-16,862,000 | - | $387,329,000 | $125,441,000 |
| Write Off | $0 | $0 | $30,321,000 | $2,575,000 |
| Restructuring And Mergern Acquisition | $42,009,000 | $7,838,000 | $1,200,000 | $-6,700,000 |
| Gain On Sale Of Security | $-15,914,000 | $-2,785,000 | $1,527,000 | - |
| Amortization | $2,622,000 | $2,405,000 | $1,559,000 | $714,000 |
| Research And Development | $1,522,066,000 | $804,522,000 | $877,387,000 | $877,090,000 |
| Selling General And Administration | $491,716,000 | $557,872,000 | $481,871,000 | $451,421,000 |
| Other Gand A | $262,268,000 | $276,074,000 | $224,529,000 | $157,569,000 |
| Salaries And Wages | $229,448,000 | $281,798,000 | $257,342,000 | $293,852,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
| Securities Amortization | - | - | - | $-11,235,000 |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,111,673,000 | $1,500,855,000 | $829,717,000 | $377,372,000 |
| Total Assets | $3,349,703,000 | $3,963,173,000 | $3,264,576,000 | $3,128,366,000 |
| Total Non Current Assets | $811,765,000 | $889,710,000 | $685,245,000 | $570,505,000 |
| Other Non Current Assets | $202,858,000 | $204,707,000 | $212,322,000 | $183,653,000 |
| Non Current Prepaid Assets | $95,948,000 | $30,345,000 | $79,670,000 | $102,962,000 |
| Non Current Deferred Assets | $2,822,000 | $2,252,000 | - | - |
| Non Current Deferred Taxes Assets | $2,822,000 | $2,252,000 | - | - |
| Goodwill And Other Intangible Assets | $28,949,000 | $26,887,000 | $29,620,000 | $7,578,000 |
| Other Intangible Assets | $28,949,000 | $26,887,000 | $29,620,000 | $7,578,000 |
| Current Assets | $2,537,938,000 | $3,073,463,000 | $2,579,331,000 | $2,557,861,000 |
| Other Current Assets | $9,201,000 | $5,025,000 | $12,478,000 | $6,821,000 |
| Prepaid Assets | $154,733,000 | $311,988,000 | $130,769,000 | $96,098,000 |
| Inventory | $914,744,000 | $749,960,000 | $322,859,000 | $203,968,000 |
| Receivables | $519,610,000 | $651,698,000 | $436,975,000 | $261,600,000 |
| Other Receivables | $104,117,000 | $34,608,000 | $29,786,000 | $41,758,000 |
| Taxes Receivable | $15,604,000 | $13,132,000 | $6,862,000 | $1,903,000 |
| Accrued Interest Receivable | $1,656,000 | $1,970,000 | $2,731,000 | $3,311,000 |
| Accounts Receivable | $398,233,000 | $601,988,000 | $400,327,000 | $214,628,000 |
| Cash Cash Equivalents And Short Term Investments | $939,650,000 | $1,354,792,000 | $1,676,250,000 | $1,989,374,000 |
| Cash And Cash Equivalents | $801,282,000 | $1,103,010,000 | $428,430,000 | $966,777,000 |
| Debt | ||||
| Net Debt | $27,692,000 | $34,114,000 | $809,568,000 | $577,515,000 |
| Total Debt | $1,039,745,000 | $1,343,070,000 | $1,396,808,000 | $1,617,359,000 |
| Long Term Debt And Capital Lease Obligation | $1,028,352,000 | $1,329,597,000 | $1,273,480,000 | $1,601,870,000 |
| Long Term Debt | $828,974,000 | $1,137,124,000 | $1,132,515,000 | $1,544,292,000 |
| Current Debt And Capital Lease Obligation | $11,393,000 | $13,473,000 | $123,328,000 | $15,489,000 |
| Current Debt | - | - | $105,483,000 | - |
| Other Current Borrowings | - | - | $105,483,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,209,081,000 | $2,435,431,000 | $2,405,239,000 | $2,743,416,000 |
| Total Non Current Liabilities Net Minority Interest | $1,113,791,000 | $1,703,747,000 | $1,751,580,000 | $2,123,812,000 |
| Other Non Current Liabilities | $1,529,000 | $49,150,000 | $41,100,000 | $36,942,000 |
| Non Current Deferred Liabilities | $83,910,000 | $325,000,000 | $437,000,000 | $485,000,000 |
| Current Liabilities | $1,095,290,000 | $731,684,000 | $653,659,000 | $619,604,000 |
| Current Deferred Liabilities | $443,397,000 | $130,256,000 | $50,416,000 | $89,244,000 |
| Payables And Accrued Expenses | $464,375,000 | $387,679,000 | $301,108,000 | $380,141,000 |
| Interest Payable | $20,714,000 | $4,192,000 | $4,395,000 | $4,956,000 |
| Payables | $285,596,000 | $231,833,000 | $178,684,000 | $108,396,000 |
| Total Tax Payable | $4,755,000 | $17,391,000 | $13,766,000 | $12,521,000 |
| Income Tax Payable | $4,755,000 | $17,391,000 | $13,766,000 | $12,521,000 |
| Accounts Payable | $280,841,000 | $214,442,000 | $164,918,000 | $95,875,000 |
| Other Current Liabilities | - | - | - | $15,489,000 |
| Equity | ||||
| Common Stock Equity | $1,140,622,000 | $1,527,742,000 | $859,337,000 | $384,950,000 |
| Total Equity Gross Minority Interest | $1,140,622,000 | $1,527,742,000 | $859,337,000 | $384,950,000 |
| Stockholders Equity | $1,140,622,000 | $1,527,742,000 | $859,337,000 | $384,950,000 |
| Gains Losses Not Affecting Retained Earnings | $272,000 | $-218,000 | $918,000 | $-1,664,000 |
| Other Equity Adjustments | $272,000 | $-218,000 | $918,000 | $-1,664,000 |
| Retained Earnings | $-4,876,984,000 | $-4,210,974,000 | $-4,446,213,000 | $-3,910,236,000 |
| Other | ||||
| Treasury Shares Number | $650,876 | - | - | - |
| Ordinary Shares Number | $104,964,220 | $96,900,496 | $93,731,831 | $87,950,117 |
| Share Issued | $105,615,096 | $96,900,496 | $93,731,831 | $87,950,117 |
| Tangible Book Value | $1,111,673,000 | $1,500,855,000 | $829,717,000 | $377,372,000 |
| Invested Capital | $1,969,596,000 | $2,664,866,000 | $2,097,335,000 | $1,929,242,000 |
| Working Capital | $1,442,648,000 | $2,341,779,000 | $1,925,672,000 | $1,938,257,000 |
| Capital Lease Obligations | $210,771,000 | $205,946,000 | $158,810,000 | $73,067,000 |
| Total Capitalization | $1,969,596,000 | $2,664,866,000 | $1,991,852,000 | $1,929,242,000 |
| Treasury Stock | $25,263,000 | $0 | - | - |
| Additional Paid In Capital | $6,042,586,000 | $5,738,924,000 | $5,304,623,000 | $4,296,841,000 |
| Capital Stock | $11,000 | $10,000 | $9,000 | $9,000 |
| Common Stock | $11,000 | $10,000 | $9,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $83,910,000 | $325,000,000 | $437,000,000 | $485,000,000 |
| Long Term Capital Lease Obligation | $199,378,000 | $192,473,000 | $140,965,000 | $57,578,000 |
| Current Deferred Revenue | $443,397,000 | $130,256,000 | $50,416,000 | $89,244,000 |
| Current Capital Lease Obligation | $11,393,000 | $13,473,000 | $17,845,000 | $15,489,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $58,607,000 | $91,119,000 | $78,732,000 | $65,946,000 |
| Current Provisions | $117,518,000 | $109,157,000 | $100,075,000 | $68,784,000 |
| Current Accrued Expenses | $178,779,000 | $155,846,000 | $122,424,000 | $271,745,000 |
| Investments And Advances | $10,568,000 | $136,873,000 | $6,527,000 | $31,321,000 |
| Other Investments | $10,568,000 | $136,873,000 | $6,527,000 | $31,321,000 |
| Net PPE | $470,620,000 | $488,646,000 | $357,106,000 | $244,991,000 |
| Accumulated Depreciation | $-280,915,000 | $-234,145,000 | $-190,970,000 | $-148,876,000 |
| Gross PPE | $751,535,000 | $722,791,000 | $548,076,000 | $393,867,000 |
| Leases | $349,726,000 | $155,073,000 | $99,989,000 | $97,328,000 |
| Construction In Progress | $5,576,000 | $165,901,000 | $91,089,000 | $23,587,000 |
| Other Properties | $260,805,000 | $278,191,000 | $238,053,000 | $156,760,000 |
| Machinery Furniture Equipment | $73,025,000 | $62,277,000 | $60,711,000 | $58,079,000 |
| Buildings And Improvements | $52,232,000 | $51,178,000 | $48,063,000 | $47,942,000 |
| Land And Improvements | $10,171,000 | $10,171,000 | $10,171,000 | $10,171,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $138,368,000 | $251,782,000 | $1,247,820,000 | $1,022,597,000 |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-315,327,000 | $-352,743,000 | $-588,338,000 | $-357,597,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-205,479,000 | $-205,787,000 | $-500,993,000 | $-325,346,000 |
| Cash Flow From Continuing Operating Activities | $-205,479,000 | $-205,787,000 | $-500,993,000 | $-325,346,000 |
| Operating Gains Losses | $14,382,000 | $24,005,000 | $403,024,000 | $131,476,000 |
| Investing Activities | ||||
| Capital Expenditure | $-109,848,000 | $-146,956,000 | $-87,345,000 | $-32,251,000 |
| Investing Cash Flow | $69,641,000 | $755,561,000 | $-165,803,000 | $-1,046,883,000 |
| Cash Flow From Continuing Investing Activities | $69,641,000 | $755,561,000 | $-165,803,000 | $-1,046,883,000 |
| Net Other Investing Changes | - | - | $102,000,000 | $-2,427,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-25,013,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $20,000,000 | $0 | $0 | $0 |
| Financing Cash Flow | $-168,344,000 | $124,806,000 | $125,004,000 | $232,507,000 |
| Cash Flow From Continuing Financing Activities | $-168,344,000 | $124,806,000 | $125,004,000 | $232,507,000 |
| Net Other Financing Charges | $-19,446,000 | - | $-6,887,000 | $-716,000 |
| Net Common Stock Issuance | $-5,013,000 | $0 | $0 | $0 |
| Common Stock Issuance | $20,000,000 | $0 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-162,588,000 | $-68,000 | $0 | $-823,232,000 |
| Interest Paid Supplemental Data | $14,913,000 | $15,856,000 | $15,923,000 | $44,418,000 |
| Income Tax Paid Supplemental Data | $37,632,000 | $22,587,000 | $15,081,000 | $1,695,000 |
| End Cash Position | $814,407,000 | $1,118,589,000 | $444,009,000 | $985,801,000 |
| Beginning Cash Position | $1,118,589,000 | $444,009,000 | $985,801,000 | $2,125,523,000 |
| Changes In Cash | $-304,182,000 | $674,580,000 | $-541,792,000 | $-1,139,722,000 |
| Proceeds From Stock Option Exercised | $18,703,000 | $124,874,000 | $131,891,000 | $-70,945,000 |
| Common Stock Payments | $-25,013,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $-162,588,000 | $-68,000 | $0 | $304,168,000 |
| Net Long Term Debt Issuance | $-162,588,000 | $-68,000 | $0 | $304,168,000 |
| Long Term Debt Payments | $-162,588,000 | $-68,000 | $0 | $-823,232,000 |
| Net Investment Purchase And Sale | $5,394,000 | $902,517,000 | $-180,458,000 | $-1,014,632,000 |
| Sale Of Investment | $295,871,000 | $2,002,112,000 | $1,868,482,000 | $923,224,000 |
| Purchase Of Investment | $-290,477,000 | $-1,099,595,000 | $-2,048,940,000 | $-1,937,856,000 |
| Net Business Purchase And Sale | $174,095,000 | $0 | $0 | - |
| Sale Of Business | $174,095,000 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-7,876,000 | $-10,000,000 | $-11,239,000 | $-1,427,000 |
| Purchase Of Intangibles | $-7,876,000 | $-10,000,000 | $-11,239,000 | $-1,427,000 |
| Net PPE Purchase And Sale | $-101,972,000 | $-136,956,000 | $-76,106,000 | $-30,824,000 |
| Purchase Of PPE | $-101,972,000 | $-136,956,000 | $-76,106,000 | $-30,824,000 |
| Change In Working Capital | $78,038,000 | $-716,606,000 | $-481,089,000 | $-39,470,000 |
| Change In Other Working Capital | $72,051,000 | $-32,160,000 | $-86,828,000 | $-89,244,000 |
| Change In Other Current Assets | $-79,784,000 | $-9,676,000 | $1,808,000 | $-27,937,000 |
| Change In Payables And Accrued Expense | $104,269,000 | $110,649,000 | $-50,135,000 | $147,572,000 |
| Change In Payable | $104,269,000 | $110,649,000 | $-50,135,000 | $147,572,000 |
| Change In Account Payable | $104,269,000 | $110,649,000 | $-50,135,000 | $147,572,000 |
| Change In Prepaid Assets | $78,840,000 | $-188,588,000 | $-12,521,000 | $42,557,000 |
| Change In Inventory | $-301,093,000 | $-395,170,000 | $-147,714,000 | $-50,780,000 |
| Change In Receivables | $203,755,000 | $-201,661,000 | $-185,699,000 | $-61,638,000 |
| Changes In Account Receivables | $203,755,000 | $-201,661,000 | $-185,699,000 | $-61,638,000 |
| Other Non Cash Items | $70,587,000 | $69,828,000 | $-98,007,000 | $19,330,000 |
| Stock Based Compensation | $123,396,000 | $184,300,000 | $182,514,000 | $233,018,000 |
| Asset Impairment Charge | $182,298,000 | $0 | $30,321,000 | $2,575,000 |
| Amortization Of Securities | $-5,291,000 | $-40,277,000 | $-46,176,000 | $-10,651,000 |
| Depreciation Amortization Depletion | $44,521,000 | $37,724,000 | $44,397,000 | $41,864,000 |
| Depreciation And Amortization | $44,521,000 | $37,724,000 | $44,397,000 | $41,864,000 |
| Earnings Losses From Equity Investments | $17,293,000 | $0 | $0 | - |
| Gain Loss On Sale Of PPE | $13,951,000 | $16,167,000 | $14,495,000 | $12,735,000 |
| Net Income From Continuing Operations | $-713,410,000 | $235,239,000 | $-535,977,000 | $-703,488,000 |
| Issuance Of Debt | - | $0 | $0 | $1,127,400,000 |
| Long Term Debt Issuance | - | $0 | $0 | $1,127,400,000 |
| Gain Loss On Investment Securities | - | $7,838,000 | $1,200,000 | $-6,700,000 |
| Purchase Of Business | - | - | - | - |
Fetched: 2026-06-11